DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials. Patients included in DIGIT-HF display a more severe HF symptom burden and higher rates of ICD/CRT

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2). In this substudy, serelaxin decreased plasma concentrations of cardiac, renal and hepatic injury markers.

Join millions who have switched to Grok.

Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: A 20-year follow-up study. In the STANISLAS cohort, initial circulating GDF-15 levels were associated with

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries – A Global Congestive Heart Failure (G-CHF) study. Reduced LVEF was associated with worse

Ischemic Injury Drives Nascent Tumor Growth Via Accelerated Hematopoietic Aging. Peripheral ischemia enhances inflammaging of hematopoietic stem cells and long-lasting alterations to antitumoral immunity, accelerating breast tumor growth. @JACCJournals @ACCinTouch @CMichaelGibson

Pop-Up Cardiovascular Screening Within Community Pharmacies and an International Sporting Event. Uncontrolled cardiovascular risk factors were prevalent during opportunistic pop-up community screening, with higher rates observed at the sporting event, rural pharmacies, and during

Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up. FFR-guided and IVUS-guided treatment strategies resulted in comparable long-term outcomes, with no significant difference in patient-oriented composite

Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology

Impact of left-heart myopathy on mitral valve stenosis assessment and interventional outcomes: an in-silico trial. Virtual patient cohorts suggest that MV intervention reduces MG but may not normalize mLAP in patients with impaired LV and LA function.

Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: Diagnostic accuracy study. At ESC HFA age-adjusted thresholds, the number of referrals required for HF diagnostic assessment are substantially reduced, but with some (likely lower risk)

Primary Left Atrial Cardiopathy in Transthyretin Amyloidosis Cardiomyopathy by Multimodality Imaging: Implications for Thrombotic Events. Primary LA cardiopathy seems to be associated with TEs in ATTR-CM, independently of AF, CHA2DS2-VASc, and LA dilatation, unlike other LVH

Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review. Cancer and cardiovascular disease are leading causes of death with shared risks and biology. Common risk factors include age,

Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up. FFR-guided and IVUS-guided treatment strategies resulted in comparable long-term outcomes, with no significant difference in patient-oriented composite

Acute heart failure in non-cardiac surgery: A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC) and the Heart Failure Association (HFA) of the ESC. Acute HF is the leading cause of hospitalization in patients over 65 years old and is linked to

RT @HemostasisToday: TAILORED-CHIP Trial: Time-Dependent Antiplatelet Therapy in High-Risk PCI.@drbennisahmed . #A….

Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial. TAILORED-CHIP trial is an investigator-initiated, multicentre, prospective randomised trial to

GLP-1 Receptor Agonist Use in Kidney Transplant Recipients. Using data from 18,016 kidney transplant recipients in the United States from 2013 to 2020, the study found that those prescribed GLP-1 receptor agonists post-transplant experienced a 49% reduction in death-censored

Rationale, design and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF). In ENVAD-HF we aimed to study safety and effect of heart failure drug

Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors. Outpatient management is feasible in most patients when cardiovascular immune-related adverse events are

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. ODYSSEY-HCM is a phase 3 trial, RCT evaluating mavacamten in 580 symptomatic nHCM patients worldwide. It assesses improvements at Week 48 in